XXXXXXXX XXXXXX (EU) 2021/383
xx dne 3. března 2021,
xxxxxx xx xxxx xxxxxxx III xxxxxxxx Xxxxxxxxxx xxxxxxxxxx a Rady (XX) x.&xxxx;1107/2009 uvedením xxxxxxx xxxxxxxxxxxx xxxxxx, xxxxx jsou xxxxxxxxxxxx xxxx xxxxxxx xxxxxxxxx xx xxxxxxx rostlin
(Text x&xxxx;xxxxxxxx pro XXX)
XXXXXXXX XXXXXX,
x&xxxx;xxxxxxx xx Smlouvu x&xxxx;xxxxxxxxx Xxxxxxxx xxxx,
x&xxxx;xxxxxxx xx nařízení Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (XX) x.&xxxx;1107/2009 xx dne 21.&xxxx;xxxxx&xxxx;2009 x&xxxx;xxxxxxx přípravků xx xxxxxxx rostlin xx xxx x&xxxx;x&xxxx;xxxxxxx xxxxxxx Rady 79/117/EHS x&xxxx;91/414/XXX&xxxx;(1), x&xxxx;xxxxxxx xx xx.&xxxx;27 odst. 2 a čl. 78 xxxx.&xxxx;2 uvedeného xxxxxxxx
xxxxxxxx x&xxxx;xxxxx důvodům:
|
(1) |
Formulační přísady xxxx xxxxxxx x&xxxx;xx.&xxxx;2 xxxx.&xxxx;3 xxxx. x) xxxxxxxx (XX) x.&xxxx;1107/2009&xxxx;xxxx xxxxx xx přípravky, xxxxx xx xxxxxxxxx x&xxxx;xxxxxxxxxxx xx xxxxxxx xxxxxxx či x&xxxx;xxxxxxxxxxx xxxx jsou x&xxxx;xxxxxxxx xxxxxxx určeny, xxxxx xxxxx xxxxxxx mezi xxxxxx xxxxx, xxxxxxxx xxx synergenty. |
|
(2) |
Formulační xxxxxxx xxxx xxxxxxxxxxxx xxxx xxxxxxx přípravků na xxxxxxx xxxxxxx, pokud xxxxxx xxxxxxx, která xxxxxxx xx aplikaci x&xxxx;xxxxxxx xx správnou xxxxx x&xxxx;xxxxxxx rostlin xxx xxxxxxxxxx skutečných xxxxxxxx xxxxxxx, xxxx xxxxxxxx xxxxxx xx xxxxxx xxxx xxxx xxxxxx xxxxx xx xxxxxxxx xxxx či xxxxxxxxxxxx účinky na xxxxxxx prostředí. Xxxxxxxxxx xxxxxxx jsou xxxxxx xxxxxxxxxxxx xxxx xxxxxxx xxxxxxxxx xx ochranu xxxxxxx, pokud jejich xxxxxxxxx xx xxxxxxxx x&xxxx;xxxxxxx se xxxxxxxx xxxxx v ochraně rostlin xxx zohlednění xxxxxxxxxx xxxxxxxx použití má xxxxxxxx xxxxxx xx xxxxxx xxxx xxxx xxxxxx anebo xxxxxxxxxxxx xxxxxx xx xxxxxxxx, xxxxxxxxx xxxxxxxx xxxx xxxxxxx xxxxxxxxx. Xxxxxx xxxxxxxxxxxx formulační xxxxxxx xxxx xxx xxxxxxx xx seznamu x&xxxx;xxxxxxx XXX xxxxxxxx (ES) x.&xxxx;1107/2009. |
|
(3) |
Xxxxxxxxxx xxxxxxx xxxx xxxxx nebo přípravky xxxxxxxxx xxxxxxxx x&xxxx;xxxxxxxx xxxxxxx v přípravcích xx xxxxxxx xxxxxxx, a jsou xxxxx xxxxxx xxxxxx x&xxxx;xxxxxxxx xxxxxxxxx. Proto xx xxxxxxxx xxxxxxxx xx xxxxxxxx xxxxxx, xxxxxxxxx xxxxxxxxx, xxxxxxxxxxx x&xxxx;xxxxxxxxxx xxx xxxxxxxxx x&xxxx;xxxxxx 3.6.2, 3.6.3, 3.6.4, 3.6.5, 3.7, 3.8.2 x&xxxx;3.10 xxxxxxx XX xxxxxxxx (XX) x.&xxxx;1107/2009 xxxx být xxxxxx relevantní xxx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxx. |
|
(4) |
Xxxxxx nepřijatelných xxxxxxxxxxxx xxxxxx by xxx xxxxx zahrnovat látky x&xxxx;xxxxxxxxxxxxxx xxxxxxxxxxx jako xxxxxxxxxxx, kategorie 1&xxxx;X&xxxx;xxxx 1X, jako mutageny, xxxxxxxxx 1&xxxx;X&xxxx;xxxx 1B, xxxx xxxx xxxxxxx xxx reprodukci, xxxxxxxxx 1&xxxx;X&xxxx;xxxx 1B, x&xxxx;xxxxxxx x&xxxx;xxxxxxxx XX xxxxxxxx Xxxxxxxxxx parlamentu x&xxxx;Xxxx (XX) x.&xxxx;1272/2008&xxxx;(2). |
|
(5) |
Xxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxx xx xxx dále xxxxxxxxx xxxxx identifikované xxxx xxxxxxxxxxxx xxxxxxxxxxxxxxx x&xxxx;xxxxxxx („XXX“) nebo vysoce xxxxxxxxxxxx x&xxxx;xxxxxx bioakumulativní („xXxX“) v souladu s čl. 57 xxxx. x) x&xxxx;x) xxxxxxxx Xxxxxxxxxx parlamentu x&xxxx;Xxxx (XX) x.&xxxx;1907/2006&xxxx;(3). |
|
(6) |
Xxxxxx xxxxxxxxxxxxxx formulačních přísad xx xxx xxxxxx xxxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxx obavy v důsledku xxxxxxxxxx xxxxxxxxxxxxxx narušení xxxxxxxxxx xxxxxxxx v souladu x&xxxx;xx.&xxxx;57 xxxx. f) xxxxxxxx (XX) č. 1907/2006 xxxx látky xxxxxxxxxxxxxx xxxx endokrinní xxxxxxxxxx xxxxx xxxxxxxx Xxxxxxxxxx xxxxxxxxxx a Rady (XX) x.&xxxx;528/2012&xxxx;(4) nebo látky xxxxxxxxxxxxxx jako perzistentní xxxxxxxxx xxxxxxxxxxxx látky („XXX“) xxxxx nařízení Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (XX) 2019/1021&xxxx;(5). |
|
(7) |
Xxxxxxxx (XX) x.&xxxx;1907/2006 xxxxxxx x&xxxx;xxxxxxx XXXX xxxxxxx xxx xxxxxxx xxxxxxxxxx xxxxx. Xxxxxxx-xx xxxxxxx uvedených xxxxx xxxxxxx formulačních xxxxxx v přípravcích xx xxxxxxx xxxxxxx omezením, xxxx xx xxx xxxxxxxx xx xxxxxx xxxxxxxxxxxx xxxxxx v příloze XXX xxxxxxxx (XX) x.&xxxx;1107/2009. |
|
(8) |
Xxxxxxx xxxxx identifikovaly xxxxxxxxxx xxxxxxx, které xxxxxxxx xx xxxxxxxxxxxx x&xxxx;xxxxxxxxxxx xx xxxxxxx xxxxxxx xxxxxxxxxx podle xxxxxxxx Xxxx 91/414/XXX&xxxx;(6) xxxx xxxxxxxx (XX) x.&xxxx;1107/2009. Takové xxxxxxxxxx xxxxxxx xxxxxxxx Xxxxxxxx, Xxxxxx, Francie, Xxxxxxx, Xxxxxx, Xxxxx, Xxxxxxxxx x&xxxx;Xxxxxx. X&xxxx;xxxxxxxxx formulačních xxxxxx by xxxxxxx x&xxxx;xxxxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxxx, xxxxxxxxx 1&xxxx;X&xxxx;xxxx 1X, xxxx mutageny, xxxxxxxxx 1 A nebo 1X, xxxx xxxx xxxxxxx xxx xxxxxxxxxx, xxxxxxxxx 1&xxxx;X&xxxx;xxxx 1X, v souladu x&xxxx;xxxxxxxx VI xxxxxxxx (XX) x.&xxxx;1272/2008, xxxxxxx xxxxxxxxxxxxxx xxxx XXX xxxx vPvB xxxxx xx.&xxxx;57 písm. x) x&xxxx;x) xxxxxxxx (ES) x.&xxxx;1907/2006, xxxxxxx identifikované xxxx látky xxxxxxxxxx xxxxxxxxx xxxxx v důsledku xxxxxxxxxx xxxxxxxxxxxxxx narušení xxxxxxxxxx činnosti v souladu x&xxxx;xx.&xxxx;57 xxxx. x) xxxxxxxx (ES) x.&xxxx;1907/2006 x&xxxx;xxxxxxx xxxxxxxxxxxxxx xxxx XXX xxxxx xxxxxxxx (XX) 2019/1021 měly xxx xxxxxxx xx xxxxxxx x&xxxx;xxxxxxx III xxxxxxxx (XX) x.&xxxx;1107/2009. |
|
(9) |
Xxxxxxx xxxxxxxxxxxxxx aminů loje (x.&xxxx;XXX 61791-26-2) v přípravcích xx ochranu xxxxxxx xxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx xxxxxxxxxx nařízením Xxxxxx (XX) 2016/1313&xxxx;(7), xxxxxxx xxxx zjištěny xxxxx x&xxxx;xxxxxxxxxxx s toxicitou xxxxxxxxxxxxxx xxxxx xxxx x&xxxx;xxxxxx potenciálem xxx xxxxxxxxx vliv xx xxxxxx zdraví. Vzhledem x&xxxx;xxxx, xx xxxxxxx xxxxx xxxxxxxxx x&xxxx;xxxxxxxxxxx xxxxxxxxxx xxxxxxxxx xxxxx, x&xxxx;xx xxxxx xxxxxx xxxxxxx na xxxxxxxxxxx xxxxxxxxx xxxxxxxxxx glyfosát, xxx xxxx xxxxxxx xxxxxxxx pro xxxxxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxx xxxxx, měly xx být xxxxxxxxxxxx xxxxx loje xxxxxx xxxxxxxx xx xxxxxx xxxxxxxxxxxx přísad x&xxxx;xxxxxxx XXX nařízení (ES) x.&xxxx;1107/2009. |
|
(10) |
Xxxxxxxxxxx xxxxxxxxxxxx Xxxxxx (XX) 2016/109&xxxx;(8) x&xxxx;(XX) 2018/619&xxxx;(9) xxxxxx xxxxxxxxx xxxxx PHMB (1600; 1.8), xxxxx CAS 27083-27-8 x&xxxx;32289-58-0, x&xxxx;XXXX (1415; 4.7), xxxxx XXX 32289-58-0 a 1802181-67-4, xxxx stávající účinné xxxxx pro xxxxxxx x&xxxx;xxxxxxxxxx xxxxxxxxxxx typu 6 (xxxxxxxxxxx xxx xxxxxxx v plechových xxxxxxx), xxxx xxxxxx xxxx xxxxxxxxx x&xxxx;xxxxxxxx nepřijatelných xxxxx xxx xxxxxx xxxxxx a životní xxxxxxxxx. Xxxxxx xxxxxxx xxxx xxxxxxxxxxx xxx xxxxxxx x&xxxx;xxxxxxxxxx xxxxxxx x&xxxx;xxxxxxxxxxx xx ochranu xxxxxxx xx proto vedlo x&xxxx;xxxxxxxxxxxxx xxxxxxx xx xxxxxx xxxxxx x&xxxx;xxxxxxx xxxxxxxxx. Proto xx xxxxx XXXX (1600; 1.8) x&xxxx;XXXX (1415; 4.7) xxxx xxx xxxxxx uvedeny xx xxxxxxx v příloze XXX xxxxxxxx (XX) x.&xxxx;1107/2009. |
|
(11) |
Xxxxxxxxxx xxxxxxx, které xxxx xxx xxxxxxx na xxxxxxx x&xxxx;xxxxxxx XXX xxxxxxxx (XX) x.&xxxx;1107/2009 xxxxx xxx xxxxxx xxxxxxxx v adjuvantech xxxxxxxxx xx xxx. Xxxxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxx pravidla pro xxxxxxxxxx xxxxxxxxx x&xxxx;xxxxxxx x&xxxx;xx.&xxxx;58 odst. 2 nařízení (XX) č. 1107/2009, xxxxx xxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxxxxxx předpisy xxxxxxxx se xxxxxxxxx, xxxxx xxxx x&xxxx;xxxxxxx x&xxxx;xx.&xxxx;81 xxxx.&xxxx;3 xxxxxxxxx xxxxxxxx. Xxxxxxx nařízení (XX) č. 1107/2009 má xx cíl xxxxxxxx xxxxxxx xx xxx xxxx xxxxxxxxx adjuvantů xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxx, xx potřeba xxxxxxxx, xxx xxxxxx xxxxxxxxx, xxxxx mají xxx smíseny x&xxxx;xxxxxxxxx xx ochranu xxxxxxx, xxxxxxxxxxxx žádné x&xxxx;xxxxxxxxx xxxxxxxxxxxxxx formulačních xxxxxx. |
|
(12) |
Xxxxxxxx xxxxxx xx xxx xxx xxxxxxxxx xxxxxxxx xxxx xx xxxxxxx xxxxxxx xxxxxxxxx xx xxxxxxx xxxxxxx a adjuvantů, xxxxx xxxx v současnosti xxxxxxxx xx jejich xxxxx, xxx xxxxx xxxxxxxx, zda xxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxx xx seznamu x&xxxx;xxxxxxx XXX xxxxxxxx (XX) x.&xxxx;1107/2009, x&xxxx;xxx mohly xxxxxxxx nebo xxxxxx xxxxxxxx xxxxxxxxx na xxxxxxx xxxxxxx x&xxxx;xxxxxxxxx xxxxxxxxxxxx xxxxxxx formulační xxxxxxx. |
|
(13) |
X&xxxx;xxxxxxxxx xx xxxxxxx xxxxxxx xxxx adjuvantů xxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxx xx seznamu x&xxxx;xxxxxxx XXX xxxxxxxx (XX) x.&xxxx;1107/2009, xxx xxx členské xxxxx xxxxx jakoukoliv xxxxxxxxx xxxxx v souladu x&xxxx;xxxxxxx&xxxx;46 xxxxxxxxx xxxxxxxx xxxx xxxxxxxx x&xxxx;xxxxxxx x&xxxx;xxxxxxxxxxxxxx xxxxxxxx xxx povolování xxxxxxxxx, by xxxxxxx xxxxx xxxx uplynout xxx xxxxxx x&xxxx;xxxxxxxxxx xxxxxxxxxx xx tři xxxxxx x&xxxx;xxx xxxxxxxxxx, xxxxxxxxxx a využití xx xxxxxxx devět xxxxxx xx datu xxxxx xxxx odnětí xxxxxxxx. |
|
(14) |
Xxxxxxxxxx xxxxxxx, které xxxx xxx uvedeny xx xxxxxxx v příloze XXX xxxxxxxx (XX) x.&xxxx;1107/2009, xxxxx xxx přítomny xxxx nezáměrné xxxxxxxxx x&xxxx;xxxxxx formulačních xxxxxxxxx, xxxxx jsou xxxx xxxxxx xxxxxxxxxx xxx xxxxxxx x&xxxx;xxxxxxxxxxx xx xxxxxxx rostlin xxxx xxxxxxxxxxx. Xxxxx by xxxxxxxxxxxx koncentrace nepřijatelných xxxxxxxxxxxx xxxxxx x&xxxx;xxxxxxxx xxxxxxxxx na ochranu xxxxxxx nebo adjuvantu xxxx být xxxxx xxx 0,1&xxxx;% xxxxxxxxxxxx (xxxx.) xxxx xxxxx xxx xxxxxxxxxx xxxxxxxxxxxx xxxxx týkající xx XXX xxxxxxxxxx (karcinogenních, xxxxxxxxxxx x&xxxx;xxxxxxxxx xxx xxxxxxxxxx), xx-xx xxxxxxxx x&xxxx;xxxxxxx VI xxxxxxxx (XX) x.&xxxx;1272/2008 xxx xxxxxxxxxxxxx formulační xxxxxxx xx xxxxxx xxxxx xxx 0,1&xxxx;% xxxxxxxxxxxx (xxxx.), aby bylo xxxxx xx xxxxxxxxx xx přijatelnou nezáměrnou xxxxxxxxx, xxxxx xxxx x&xxxx;xxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxxxxxxx xxxxx xxxxxxxx xxxx xxxxx. |
|
(15) |
Xxxxxxxx xxxxxxxxx xxxxx xxxxxxxxx xxxx x&xxxx;xxxxxxx xx xxxxxxxxxxx Xxxxxxx xxxxxx xxx rostliny, zvířata, xxxxxxxxx x&xxxx;xxxxxx, |
XXXXXXX XXXX XXXXXXXX:
Článek 1
Příloha XXX xxxxxxxx (XX) x.&xxxx;1107/2009 se xxxx v souladu x&xxxx;xxxxxxxx xxxxxx nařízení.
Xxxxxx&xxxx;2
Xxxxxxx xxxxx, xxxxx xxxxxxx xxxxxxxx pro xxxxxxxxx xx xxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxx xx xxxxxxx x&xxxx;xxxxxxx XXX xxxxxxxx (ES) x.&xxxx;1107/2009, xx xxxxx xxxxxx xxxxxxxx, xxxxxxx xxxxxxxx xxxxx xxxx odejmou xx nejdříve, xxxxx xxxxxxxxxx do 24.&xxxx;xxxxxx 2023.
Xxxxxx&xxxx;3
Xxxxxxx xxxxx xxxxxxxx xxxxxxx xx xxx xxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxx formulační přísady xxxxxxx xx seznamu x&xxxx;xxxxxxx XXX nařízení (XX) x.&xxxx;1107/2009, xx xxxxx xxxxxx xxxxxxxx.
Xxxxxxx xxxxx, které xxxxxxxx xxxxxxxxx obsahující xxxxxxxxxx xxxxxxx xxxxxxx xx xxxxxxx x&xxxx;xxxxxxx III xxxxxxxx (XX) x.&xxxx;1107/2009, xx xxxxx xxxxxx xxxxxxxx, xxxxxxx povolení xxxxx xxxx odejmou xx nejdříve, avšak xxxxxxxxxx do 24.&xxxx;xxxxxx 2023.
Xxxxxx&xxxx;4
Xxxxxxxxx xxxxxxxx lhůta xxxxxxx členskými xxxxx x&xxxx;xxxxxxx x&xxxx;xxxxxxx&xxxx;46 nařízení (XX) x.&xxxx;1107/2009 nebo xxxxxxxxxxxxxx předpisy xxx xxxxxxxxxx adjuvantů xxxx xxx xx xxxxxxxxx x&xxxx;xxxx xxxxxxxx xxx xxxxxx x&xxxx;xxxxxxxxxx xxxxxxxxxx xx xxx xxxxxx x&xxxx;xxx odstranění, xxxxxxxxxx x&xxxx;xxxxxxx xx xxxxxxx xxxxx xxxxxx xx xxxx změny xxxx xxxxxx xxxxxxxx uvedených x&xxxx;xxxxxxxx 2 a 3.
Xxxxxx&xxxx;5
Xxxx nařízení vstupuje x&xxxx;xxxxxxxx dvacátým xxxx xx vyhlášení x&xxxx;Xxxxxxx xxxxxxxx Evropské xxxx.
Xxxx xxxxxxxx xx xxxxxxx v celém xxxxxxx x&xxxx;xxxxx použitelné xx xxxxx xxxxxxxxx xxxxxxx.
X&xxxx;Xxxxxxx xxx 3.&xxxx;xxxxxx 2021.
Xx Xxxxxx
xxxxxxxxxxx
Xxxxxx VON XXX XXXXX
(1)&xxxx;&xxxx;Xx. xxxx. X&xxxx;309, 24.11.2009, x.&xxxx;1.
(2)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (XX) x.&xxxx;1272/2008 xx dne 16.&xxxx;xxxxxxxx&xxxx;2008 x&xxxx;xxxxxxxxxxx, xxxxxxxxxx x&xxxx;xxxxxx látek x&xxxx;xxxxx, x&xxxx;xxxxx a zrušení xxxxxxx 67/548/XXX x&xxxx;1999/45/XX x&xxxx;x&xxxx;xxxxx xxxxxxxx (ES) x.&xxxx;1907/2006 (Xx. xxxx. X&xxxx;353, 31.12.2008, s. 1).
(3) Nařízení Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (XX) x.&xxxx;1907/2006 xx xxx 18.&xxxx;xxxxxxxx&xxxx;2006 x&xxxx;xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx x&xxxx;xxxxxxxxx chemických xxxxx, x&xxxx;xxxxxxx Evropské xxxxxxxx xxx chemické xxxxx, x&xxxx;xxxxx xxxxxxxx 1999/45/XX x&xxxx;x&xxxx;xxxxxxx nařízení Xxxx (XXX) x.&xxxx;793/93, xxxxxxxx Komise (XX) x.&xxxx;1488/94, xxxxxxxx Xxxx 76/769/XXX x&xxxx;xxxxxxx Xxxxxx 91/155/XXX, 93/67/XXX, 93/105/ES x&xxxx;2000/21/XX (Úř. věst. X&xxxx;396, 30.12.2006, x.&xxxx;1).
(4)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (XX) x.&xxxx;528/2012 ze xxx 22.&xxxx;xxxxxx&xxxx;2012 o dodávání xxxxxxxxxx xxxxxxxxx xx xxx x&xxxx;xxxxxx xxxxxxxxx (Xx. věst. X&xxxx;167, 27.6.2012, x.&xxxx;1).
(5)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (EU) 2019/1021 xx xxx 20.&xxxx;xxxxxx&xxxx;2019 o perzistentních organických xxxxxxxxxxxxxx xxxxxxx (Xx. xxxx. L 169, 25.6.2019, x.&xxxx;45).
(6)&xxxx;&xxxx;Xxxxxxxx Xxxx 91/414/XXX xx dne 15. července 1991 x&xxxx;xxxxxxx xxxxxxxxx xx xxxxxxx xxxxxxx na xxx (Xx. xxxx. X&xxxx;230, 19.8.1991, x.&xxxx;1).
(7)&xxxx;&xxxx;Xxxxxxxxx xxxxxxxx Xxxxxx (EU) 2016/1313 xx dne 1.&xxxx;xxxxx&xxxx;2016, xxxxxx xx xxxx xxxxxxxxx xxxxxxxx (XX) x.&xxxx;540/2011, xxxxx xxx x&xxxx;xxxxxxxx xxxxxxxxx xxxxxx látky xxxxxxxxx (Xx. věst. L 208, 2.8.2016, x.&xxxx;1).
(8)&xxxx;&xxxx;Xxxxxxxxx xxxxxxxxxx Xxxxxx (EU) 2016/109 xx xxx 27.&xxxx;xxxxx&xxxx;2016 x&xxxx;xxxxxxxxxxx XXXX (1600; 1.8) xxxx xxxxxxxxx xxxxxx xxxxx xxx xxxxxxx x&xxxx;xxxxxxxxxx přípravcích xxxxxxxx xxx xxxx xxxxxxxxx 1, 6 x&xxxx;9 (Úř. věst. X&xxxx;21, 28.1.2016, x.&xxxx;84).
(9)&xxxx;&xxxx;Xxxxxxxxx xxxxxxxxxx Komise (XX) 2018/619 ze xxx 20.&xxxx;xxxxx&xxxx;2018 x&xxxx;xxxxxxxxxxx PHMB (1415; 4.7) jako xxxxxxxxx účinné látky xxx xxxxxxx x&xxxx;xxxxxxxxxx xxxxxxxxxxx typu 1, 5 a 6 (Xx. xxxx. L 102, 23.4.2018, x.&xxxx;21).
XXXXXXX
Xxxxxxx XXX nařízení (XX) x.&xxxx;1107/2009 se xxxxxxxxx tímto:
„PŘÍLOHA XXX
Xxxxxx xxxxxxxxxxxx xxxxxx, xxxxx xxxx xxxxxxxxxxxx jako xxxxxxx xxxxxxxxx na xxxxxxx xxxxxxx, xxxxxxx x&xxxx;xxxxxx&xxxx;27&xxxx;&xxxx;(1)
|
X. |
Xxxxx |
Xxxxx XX/xxxx xxxxx |
Xxxxx XXX |
Xxxxx XX |
Xxxxxxxxxxx/xxxx xxxxxxxxxx |
|
1. |
1-xxxxx-2,3-xxxxxxxxxxx |
xxxxxxxxxxxxxx; 2,3-xxxxxxxxxxx-xxxxxxx |
106-89-8 |
203-439-8 |
xxxxxxxxxxxx xxx. 1X |
|
2. |
1,2-xxxxxxxxxxxx |
1,2-xxxxxxxxxxxx; xxxxx, 1,2-xxxxxxx- |
107-06-2 |
203-458-1 |
xxxxxxxxxxxx xxx. 1B |
|
3. |
2-ethoxyethanol |
2-ethoxyethanol; ethanol, 2-xxxxxx- |
110-80-5 |
203-804-1 |
xxxxxxx xxx reprodukci xxx. 1B |
|
4. |
2-ethoxyethyl-acetát |
2-ethoxyethanol-acetát; xxxxxxx, 2-xxxxxx-, 1-xxxxxx |
111-15-9 |
203-839-2 |
xxxxxxx pro xxxxxxxxxx xxx. 1X |
|
5. |
1-xxxxxxxxxxxxxxx-2-xx |
1-xxxxxxxxxxxxxxx-2-xx; X-xxxxx-2-xxxxxxxxxx |
2687-91-4 |
220-250-6 |
xxxxxxx xxx xxxxxxxxxx xxx. 1X |
|
6. |
2-xxxxxxxxxxxxxx |
2-xxxxxxxxxxxxxx; xxxxxxx, 2-xxxxxxx- |
109-86-4 |
203-713-7 |
xxxxxxx pro xxxxxxxxxx kat. 1X |
|
7. |
2-xxxxxxxxxxxx-xxxxxx |
2-xxxxxxxxxxxx-xxxxxx; xxxxxxx, 2-xxxxxxx-, 1-xxxxxx; 2-xxxxxxxxxxxxxx-xxxxxx |
110-49-6 |
203-772-9 |
xxxxxxx xxx xxxxxxxxxx xxx. 1X |
|
8. |
2-xxxxxxxxxxxxx-1-xx |
2-xxxxxxxxxxxxx-1-xx; 1-xxxxxxxx, 2-xxxxxxx- |
1589-47-5 |
216-455-5 |
xxxxxxx pro reprodukci xxx. 1X |
|
9. |
1-xxxxxxxxxxxxxxxx-2-xx |
1-xxxxxx-2-xxxxxxxxxx; 2-xxxxxxxxxxxx, 1-xxxxxx- |
872-50-4 |
212-828-1 |
xxxxxxx xxx reprodukci kat. 1X |
|
10. |
2-xxxxxxxxxxx |
2-xxxxxxxxxxx; xxxxxx, 2-xxxxx- |
79-46-9 |
201-209-1 |
xxxxxxxxxxxx xxx. 1X |
|
11. |
xxxxxxxxxx xxxx, xxxxxxxxxxxx |
xxxxxxxxxx xxxx, xxxxxxxxxxxx; xxxxxxxxxxxx xxxx xxxx |
61791-26-2 |
xxxxx nebo xxxxxxxxx xxxxx xxxxxxxxxxx x&xxxx;xxxxxxxxxxxxx xxxxxx xx lidské xxxxxx xxxx životní xxxxxxxxx |
|
|
12. |
xxxxxxxxxx xxxx, ethoxylované x&xxxx;xxxxxxxxxxxxx |
xxxxxxxxxx loje, xxxxxxxxxxxx x&xxxx;xxxxxxxxxxxxx; xxxxxxxxxxxx a propoxylovaný xxxx xxxx |
68213-26-3 |
xxxxx xxxx xxxxxxxxx xxxxx související s potenciálními xxxxxx xx xxxxxx xxxxxx xxxx xxxxxxx xxxxxxxxx |
|
|
13. |
xxxxxxxxx xxxxxx |
xxxxxxxxxxxx xxxxxx; xxxxxx, xxxxxxxxxxxx |
77536-66-4 |
xxxxxxxxxxxx kat. 1&xxxx;X |
|
|
14. |
xxxxxxxxx xxxxxx; xxxxxx, amositový |
12172-73-5 |
karcinogenní xxx. 1&xxxx;X |
||
|
15. |
xxxxxxxxxxxx xxxxxx; xxxxxx, xxxxxxxxxxxx |
77536-67-5 |
xxxxxxxxxxxx xxx. 1&xxxx;X |
||
|
16. |
xxxxxxxxxxxx xxxxxx; xxxxxx, xxxxxxxxxxxx |
12001-29-5 |
xxxxxxxxxxxx kat. 1 A |
||
|
17. |
krocidolitový xxxxxx; xxxxxx, xxxxxxxxxxxxx |
12001-28-4 |
xxxxxxxxxxxx xxx. 1&xxxx;X |
||
|
18. |
xxxxxxxxxxx xxxxxx; xxxxxx, xxxxxxxxxxx |
77536-68-6 |
xxxxxxxxxxxx xxx. 1&xxxx;X |
||
|
19. |
xxxxxx |
xxxxxx |
71-43-2 |
200-753-7 |
xxxxxxxxxxxx kat. 1&xxxx;X/ xxxxxxxxx xxx. 1X |
|
20. |
xxxxx[xxx]xxxxxxx&xxxx;&xxxx;(2); xxxxx[xxx]xxxxxxxx |
xxxxx[xxx]xxxxxxx; xxxxx[x]xxxxx |
50-32-8 |
200-028-5 |
xxxxxxxxxxxx xxx. 1X/xxxxxxxxx kat. 1X/ xxxxxxx xxx reprodukci xxx. 1X |
|
21. |
xxx(2-xxxxxxxxxxxx)xxxxxx-1,2-xxxxxxxxxxxx |
xxxxxxxxxx-xxxxxx |
84-69-5 |
201-553-2 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 písm. f) xxxxxxxx XXXXX – xxxxxx zdraví), xxxxxxx xxx reprodukci xxx. 1X |
|
22. |
xxxxxxxx boritá |
kyselina xxxxxx |
10043-35-3 11113-50-1 |
233-139-2 234-343-4 |
xxxxxxx xxx xxxxxxxxxx kat. 1X |
|
23. |
xxxxxxxxxxx xxxxxxx |
xxxxxxxxxxx xxxxxxx; xxxxxxxxxxx disodný, bezvodý |
12008-41-2 |
234-541-0 |
toxické xxx reprodukci kat. 1X |
|
24. |
xxxxxxxxxxx xxxxxxx, xxxxxxxxxxx |
xxxxxxxx xxxxxx, disodná xxx, xxxxxxxxxxx |
12280-03-4 |
234-541-0 |
xxxxxxx xxx xxxxxxxxxx xxx. 1X |
|
25. |
xxxxxxxxxxxx xxxxxxx, xxxxxxx |
xxxxxxxxxxxx xxxxxxx, xxxxxxx; xxxxx-xxxxxxx-xxxx |
1330-43-4 |
215-540-4 |
xxxxxxx xxx xxxxxxxxxx xxx. 1X |
|
26. |
xxxxxxxxxxxx xxxxxxx, xxxxxxxxxx |
xxxxx |
1303-96-4 |
215-540-4 |
xxxxxxx xxx xxxxxxxxxx xxx. 1X |
|
27. |
xxxxxxxxxxxx xxxxxxx, xxxxxxxxxxx |
xxxxx-xxxxxxx-xxxx, xxxxxxxxxxx |
12179-04-3 |
215-540-4 |
xxxxxxx xxx xxxxxxxxxx xxx. 1X |
|
28. |
xxxxxxxx orthoboritá, xxxxx sůl |
kyselina xxxxxxxxxxx, xxxxx xxx; kyselina xxxxxx, xxxxx xxx |
13840-56-7 |
237-560-2 |
xxxxxxx xxx xxxxxxxxxx kat. 1X |
|
29. |
xxxxxxxxxxxx xxxxxxx, xxxxxxxxxx |
xxxxxxxxxxxx xxxxxxx, xxxxxxxxxx; xxxxx-xxxxxxx-xxxx, xxxxxxxxxx |
12267-73-1 |
235-541-3 |
xxxxxxx xxx xxxxxxxxxx kat. 1X |
|
30. |
xxxx-1,3-xxxx |
xxxx-1,3-xxxx; 1,3-xxxxxxxx |
106-99-0 |
203-450-8 |
xxxxxxxxxxxx xxx. 1&xxxx;X/ xxxxxxxxx xxx. 1X |
|
31. |
xxxxx xxxxxxxxxx ≥&xxxx;0,1&xxxx;% xxxxxxxxx (č. ES 203-450-8) |
xxxxx |
106-97-8 |
203-448-7 |
xxxxxxxxxxxx xxx. 1&xxxx;X |
|
32. |
xxxxxx(xxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx-xxxxxxxxxxxx), (xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx-xxxxxxxxxxxx) |
xxxxxxxx, N,N“’-1,6-hexandiylbis[N’-kyano-, xxxxxxx x&xxxx;1,6-xxxxxxxxxxxxx, hydrochlorid; poly[iminokarbonimidoyliminokarbonimidoylimino-1,6-hexandiyl], xxxxxxxxxxxx; xxxxxxxx, X-xxxxx-, xxxxx. x&xxxx;1,6-xxxxxxxxxxxxx (2:1), xxxxxxx x&xxxx;1,6-xxxxxxxxxxxxx, xxxxxxxxxxxx (1:2); XXXX |
27083-27-8 x 32289-58-0 x 1802181-67-4 |
xxxxxxxxxxx xxx xxxxxxx x&xxxx;xxxxxxxxxx xxxxxxxxxxx xxxx 6 (xxxxxxxxxxx xxx výrobky x&xxxx;xxxxxxxxxx xxxxxxx) |
|
|
33. |
xxxxxxx-xxxxxx |
x-xxxxx-xxxxxx; xxxxxxx-xxxxxx-1,2-xxxxxxxxxxxx |
84-74-2 |
201-557-4 |
xxxxxxxxxx vyvolávající xxxxxxxx xxxxxxxxxx činnosti (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxx xxxxxx), toxické xxx xxxxxxxxxx xxx. 1X |
|
34. |
xxxxxxxxx (ropné), hydrogenované xxxxx naftenické x&xxxx;xxxxxxx ≥&xxxx;3,0&xxxx;% xxxxxxxxxxxx xxxxx xxxxxxxxxxxxxxxx xx xxxxxxxxxxxxxxxxx (XXXX) (xxxxxxxxx xxxxxxxx XX 346) |
64742-52-5 |
265-155-0 |
xxxxxxxxxxxx kat. 1X |
|
|
35. |
xxxxxxxxx (xxxxx), xxxxxxxxxxxxx xxxxx xxxxxxxxxxx x&xxxx;xxxxxxx ≥&xxxx;3,0&xxxx;% xxxxxxxxxxxx látek xxxxxxxxxxxxxxxx do xxxxxxxxxxxxxxxxx (XXXX) (xxxxxxxxx xxxxxxxx XX 346) |
64742-54-7 |
265-157-1 |
xxxxxxxxxxxx kat. 1X |
|
|
36. |
xxxxxxxxx (xxxxx), xxxxxxxxxxxxx xxxxx xxxxxxxxxx x&xxxx;xxxxxxx ≥&xxxx;3,0&xxxx;% xxxxxxxxxxxx xxxxx xxxxxxxxxxxxxxxx xx dimethylsulfoxidu (XXXX) (stanovení xxxxxxxx XX 346) |
64742-53-6 |
265-156-6 |
xxxxxxxxxxxx xxx. 1X |
|
|
37. |
xxxxxxxxx (xxxxx), hydrogenované xxxxx parafinické s obsahem ≥&xxxx;3,0&xxxx;% xxxxxxxxxxxx xxxxx xxxxxxxxxxxxxxxx xx dimethylsulfoxidu (XXXX) (stanovení postupem XX 346) |
64742-55-8 |
265-158-7 |
xxxxxxxxxxxx kat. 1X |
|
|
38. |
xxxxxxxxx (xxxxx), xxxxxxxxxxxxxx xxxxxxxxxxxxxx těžké parafinické x&xxxx;xxxxxxx ≥ 3,0 % xxxxxxxxxxxx xxxxx xxxxxxxxxxxxxxxx xx xxxxxxxxxxxxxxxxx (DMSO) (xxxxxxxxx xxxxxxxx XX 346) |
64742-65-0 |
265-169-7 |
xxxxxxxxxxxx xxx. 1X |
|
|
39. |
xxxxxxxxx (xxxxx), xxxxxxxxxxxxxx xxxxxxxxxx těžké xxxxxxxxxxx x&xxxx;xxxxxxx ≥&xxxx;3,0&xxxx;% xxxxxxxxxxxx látek extrahovatelných xx dimethylsulfoxidu (XXXX) (xxxxxxxxx xxxxxxxx XX 346) |
64741-88-4 |
265-090-8 |
xxxxxxxxxxxx kat. 1X |
|
|
40. |
xxxxxxxxx (xxxxx), xxxxxxxxxxxxxx xxxxxxxxxx xxxxx xxxxxxxxxxx x&xxxx;xxxxxxx ≥&xxxx;3,0&xxxx;% xxxxxxxxxxxx látek xxxxxxxxxxxxxxxx do xxxxxxxxxxxxxxxxx (XXXX) (stanovení xxxxxxxx XX 346) |
64741-89-5 |
265-091-3 |
xxxxxxxxxxxx xxx. 1X |
|
|
41. |
xxxxxxxxxxx |
xxxxxxxxxxx; xxxxxx; xxxxxxxxxx |
75-21-8 |
200-849-9 |
xxxxxxxxxxxx xxx. 1X/ xxxxxxxxx kat. 1X |
|
42. |
xxxxxxxxxxx |
xxxxxxxxxxx; xxxxxxxx; xxxxxxxx; xxxxxx |
50-00-0 |
200-001-8 |
xxxxxxxxxxxx xxx. 1X |
|
43. |
xxxxxxxx |
xxxxxxxx; xxxxxxxxxx |
75-12-7 |
200-842-0 |
xxxxxxx xxx xxxxxxxxxx xxx. 1X |
|
44. |
xxxxxxxx (xxxxxxxxxx ≥&xxxx;0,1&xxxx;% butadienu (x.&xxxx;XX 203-450-8)) |
xxxxxxxx; xxxxxx, 2-xxxxxx- |
75-28-5 |
200-857-2 |
xxxxxxxxxxxx xxx. 1&xxxx;X/ xxxxxxxxx xxx. 1X |
|
45. |
xxxxxx oleje (ropné), X20–50, xxxxxxxxxxxxx neutrální xxxxx, xxxxxxxxxxxxxx x&xxxx;xxxxxxx ≥&xxxx;3,0&xxxx;% hmotnostních látek xxxxxxxxxxxxxxxx do xxxxxxxxxxxxxxxxx (XXXX) (xxxxxxxxx postupem XX 346) |
72623-85-9 |
276-736-3 |
xxxxxxxxxxxx xxx. 1X |
|
|
46. |
xxxxxx xxxxx (ropné), X15–30, hydrogenované xxxxxxxxx xxxxx, s obsahem ≥&xxxx;3,0&xxxx;% xxxxxxxxxxxx xxxxx xxxxxxxxxxxxxxxx xx xxxxxxxxxxxxxxxxx (XXXX) (xxxxxxxxx xxxxxxxx XX 346) |
72623-86-0 |
276-737-9 |
xxxxxxxxxxxx kat. 1X |
|
|
47. |
xxxxxx xxxxx (ropné), X20–50, xxxxxxxxxxxxx neutrální ropné, x&xxxx;xxxxxxx ≥&xxxx;3,0&xxxx;% xxxxxxxxxxxx xxxxx xxxxxxxxxxxxxxxx xx xxxxxxxxxxxxxxxxx (XXXX) (xxxxxxxxx xxxxxxxx XX 346) |
72623-87-1 |
276-738-4 |
xxxxxxxxxxxx xxx. 1B |
|
|
48. |
mazací xxxxx (xxxxx), X17–32, rozpouštědlově xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxx, x&xxxx;xxxxxxx ≥&xxxx;3,0&xxxx;% hmotnostních xxxxx extrahovatelných do xxxxxxxxxxxxxxxxx (DMSO) (xxxxxxxxx xxxxxxxx XX 346) |
101316-70-5 |
309-875-6 |
karcinogenní xxx. 1X |
|
|
49. |
xxxxxxxxx frakce (xxxxx), xxxxx xxxxxxx, xxxxxxxx rozvětvený řetězec X9–X12, x&xxxx;xxxxxxx ≥ 0,1 % xxxxxxx (x.&xxxx;XX 200-753-7) |
64741-65-7 |
265-067-2 |
xxxxxxxxxxxx xxx. 1X/ xxxxxxxxx xxx. 1X |
|
|
50. |
xxxxxxxxx xxxxxx (xxxxx), xxxxxxxxxxxx xxxxxxxx xxxxx, xxxxxxxx C7–C12, x&xxxx;xxxxxxx ≥&xxxx;0,1&xxxx;% xxxxxxx (č. ES 200-753-7) |
64742-82-1 |
265-185-4 |
xxxxxxxxxxxx xxx. 1&xxxx;X/ xxxxxxxxx xxx. 1B |
|
|
51. |
benzínová xxxxxx (xxxxx), hydrogenačně xxxxxxxx xxxxx, dearomatizovaná, xxxxxxxx x&xxxx;xxxxxxxx x&xxxx;xxxxxxxxxxxxx X7, x&xxxx;xxxxxxx ≥&xxxx;0,1&xxxx;% benzenu (x.&xxxx;XX 200-753-7) |
92045-53-9 |
295-434-2 |
xxxxxxxxxxxx xxx. 1&xxxx;X/ xxxxxxxxx xxx. 1X |
|
|
52. |
xxxxxxxxx xxxxxx (ropná), hydrogenovaná xxxxx, xxxxxxxx X6–X13, x&xxxx;xxxxxxx ≥ 0,1 % xxxxxxx (x.&xxxx;XX 200-753-7) |
64742-48-9 |
265-150-3 |
karcinogenní xxx. 1&xxxx;X/ xxxxxxxxx xxx. 1B |
|
|
53. |
benzínová xxxxxx (ropná), lehká xxxxxxxxxx, xxxxxxxx X8–X10, x&xxxx;xxxxxxx ≥&xxxx;0,1&xxxx;% benzenu (x.&xxxx;XX 200-753-7) |
64742-95-6 |
265-199-0 |
xxxxxxxxxxxx kat. 1&xxxx;X/ xxxxxxxxx kat. 1X |
|
|
54. |
xxxxxxxxxxx |
xxxxxxxxxxx; xxxxxx, xxxxx- |
98-95-3 |
202-716-0 |
xxxxxxx pro xxxxxxxxxx xxx. 1X |
|
55. |
X-xxxxxxxxxxxxxx |
X-xxxxxxxxxxxxxx; xxxxxxxx, X-xxxxxx- |
123-39-7 |
204-624-6 |
xxxxxxx xxx xxxxxxxxxx xxx. 1X |
|
56. |
xxxxxxxxxxx: xxxxx x&xxxx;xxxxxxxxx x/xxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx x&xxxx;xxxxxx 9 xxxxxx xxxxxxxxxx xxxxxxxx x&xxxx;xxxxxxx na xxxxxxxxx xxxxxx, xxxxxxxxxx xxxxxx xxxxx, xxxxx xxxxxxxx xxxxxxxxx z individuálních xxxxxxx xxxx jejich kombinaci |
4-(3,5-dimethylheptan-3-yl)fenol; fenol, 4-(1-xxxxx-1,3-xxxxxxxxxxxxxx)-; 4-(1-xxxxx-1,3-xxxxxxxxxxxxxx)xxxxx |
186825-36-5 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
|
57. |
4-(3,6-xxxxxxxxxxxxxx-3-xx)xxxxx; xxxxx, 4-(1-xxxxx-1,4-xxxxxxxxxxxxxx)-; 4-(1-xxxxx-1,4-xxxxxxxxxxxxxx)xxxxx |
142731-63-3 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx endokrinní činnosti (xx.&xxxx;57 písm. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
58. |
4-(2-xxxxxxxxxxx-2-xx)xxxxx; x-(1,1-xxxxxxxxxxxxxx)xxxxx; xxxxx, 4-(1,1-xxxxxxxxxxxxxx)- |
30784-30-6 |
250-339-5 |
xxxxxxxxxx xxxxxxxxxxxx narušení xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) nařízení REACH – xxxxxxx prostředí) |
|
|
59. |
4-(3-methyloktan-3-yl)fenol; fenol, 4-(1-xxxxx-1-xxxxxxxxxxx)-; 4-(1-xxxxx-1-xxxxxxxxxxx)xxxxx |
52427-13-1 |
257-907-1 |
xxxxxxxxxx vyvolávající xxxxxxxx xxxxxxxxxx xxxxxxxx (čl. 57 xxxx. x) nařízení XXXXX – životní xxxxxxxxx) |
|
|
60. |
4-xxxxxxxxxx x-xxxxxxxxxx; xxxxx, 4-xxxxx- |
104-40-5 |
203-199-4 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx činnosti (xx.&xxxx;57 xxxx. x) xxxxxxxx REACH – xxxxxxx xxxxxxxxx) |
|
|
61. |
xxxxxxxxxxxxx |
11066-49-2 |
234-284-4 |
xxxxxxxxxx vyvolávající xxxxxxxx endokrinní xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx REACH – xxxxxxx xxxxxxxxx) |
|
|
62. |
x-xxxxxxxxxxxxx; xxxxx, 4-xxxxxxxx- |
26543-97-5 |
247-770-6 |
xxxxxxxxxx xxxxxxxxxxxx narušení endokrinní xxxxxxxx (xx.&xxxx;57 písm. x) xxxxxxxx XXXXX – xxxxxxx prostředí) |
|
|
63. |
nonylfenol; fenol, xxxxx- |
25154-52-3 |
246-672-0 |
xxxxxxxxxx xxxxxxxxxxxx narušení xxxxxxxxxx xxxxxxxx (čl. 57 xxxx. f) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
|
64. |
xxxxx, 4-(1-methyloktyl)-; p-(1-methyloktyl)fenol |
17404-66-9 |
241-427-4 |
vlastnosti vyvolávající xxxxxxxx endokrinní xxxxxxxx (xx.&xxxx;57 xxxx. f) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
|
65. |
xxxxx, 4-nonyl-, xxxxxxxxxx |
84852-15-3 |
284-325-5 |
xxxxxxxxxx xxxxxxxxxxxx narušení xxxxxxxxxx xxxxxxxx (čl. 57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
|
66. |
xxxxx, xxxxx-, xxxxxxxxxx |
90481-04-2 |
291-844-0 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx prostředí) |
|
|
67. |
nonylfenoly, xxxxxxxxxxxx: xxxxx s lineárním x/xxxx xxxxxxxxxxx alkylovým xxxxxxxx x&xxxx;xxxxxx 9 xxxxxx xxxxxxxxxx xxxxxxxx s fenolem xx xxxxxxxxx xxxxxx, xxxxxxxxxxxx, xxxxxxxxxx xxxxxx xxxxx, xxxxx obsahují xxxxxxxxx x&xxxx;xxxxxxxxxxxxxx xxxxxxx xxxx xxxxxx kombinaci |
nonylfenol, xxxxxxxxxxxx; xxxx(xxx-1,2-xxxxxxxxx), α-(xxxxxxxxxx)-ω-xxxxxxx- |
500-024-6 |
xxxxxxxxxx vyvolávající xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx prostředí) |
|
|
68. |
4-nonylfenol, rozvětvený, xxxxxxxxxxxx, 1–2,5 xxx; xxxx(xxx-1,2-xxxxxxxxx), α-(4-xxxxxxxxxx)-ω-xxxxxxx-, rozvětvený |
500-315-8 |
vlastnosti xxxxxxxxxxxx xxxxxxxx endokrinní xxxxxxxx (xx.&xxxx;57 písm. x) xxxxxxxx REACH – xxxxxxx xxxxxxxxx) |
||
|
69. |
4-xxxxxxxxxx, ethoxylovaný, 1–2,5 mol |
500-045-0 |
vlastnosti xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx činnosti (xx.&xxxx;57 xxxx. f) xxxxxxxx XXXXX – xxxxxxx prostředí) |
||
|
70. |
2-(2-{2-[2-(4-nonylfenoxy)ethoxy]ethoxy}ethoxy)ethan-1-ol; 2-[2-[2-[2-(4-nonylfenoxy)ethoxy]ethoxy]ethoxy]ethanol; ethanol, 2-[2-[2-[2-(4-nonylfenoxy)ethoxy]ethoxy]ethoxy]- |
7311-27-5 |
230-770-5 |
vlastnosti xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (čl. 57 xxxx. x) xxxxxxxx REACH – xxxxxxx xxxxxxxxx) |
|
|
71. |
2-[2-(4-xxxxxxxxxxx)xxxxxx]xxxxxxx; xxxxxxx, 2-[2-(4-xxxxxxxxxxx)xxxxxx]- |
20427-84-3 |
243-816-4 |
xxxxxxxxxx xxxxxxxxxxxx narušení xxxxxxxxxx činnosti (xx.&xxxx;57 xxxx. f) nařízení XXXXX – životní xxxxxxxxx) |
|
|
72. |
20-(4-xxxxxxxxxxx)-3,6,9,12,15,18-xxxxxxxxxxxxx-1-xx; 3,6,9,12,15,18-xxxxxxxxxxxxxx-1-xx, 20-(4-nonylfenoxy)- |
27942-27-4 |
248-743-1 |
vlastnosti xxxxxxxxxxxx xxxxxxxx endokrinní xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
|
73. |
2-[2-[2-[2-(4-xxxxxxxxxxx)xxxxxx]xxxxxx]xxxxxx]xxxxx-1-xx; xxxxxxx, 2-[2-[2-[2-(4-nonylfenoxy)ethoxy]ethoxy]ethoxy]- |
7311-27-5 |
vlastnosti xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) nařízení XXXXX – životní xxxxxxxxx) |
||
|
74. |
26-(4-xxxxxxxxxxx)-3,6,9,12,15,18,21,24-xxxxxxxxxxxxxxxx-1-xx; 3,6,9,12,15,18,21,24-xxxxxxxxxxxxxxxx-1-xx, 26-(4-xxxxxxxxxxx)- |
14409-72-4 |
xxxxxxxxxx xxxxxxxxxxxx narušení xxxxxxxxxx činnosti (xx.&xxxx;57 xxxx. f) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
75. |
17-(4-xxxxxxxxxxx)-3,6,9,12,15-xxxxxxxxxxxxxxxxxx-1-xx; 3,6,9,12,15-xxxxxxxxxxxxxxxxxx-1-xx, 17-(4-nonylfenoxy)- |
34166-38-6 |
vlastnosti xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
76. |
xxxx(xxx-1,2-xxxxxxxxx), α-(4-xxxxxxxxxx)-ω-xxxxxxx-, xxxxxxxxxx |
127087-87-0 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
77. |
xxxx(xxx-1,2-xxxxxxxxx), α-(4-xxxxxxxxxx)-ω-xxxxxxx- |
26027-38-3 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx endokrinní xxxxxxxx (xx.&xxxx;57 písm. x) xxxxxxxx XXXXX – xxxxxxx prostředí) |
||
|
78. |
ethanol, 2-(4-xxxxxxxxxxx)- |
104-35-8 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 písm. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
79. |
xxxxxxxxxxxxx, xxxxxxxxxxxx; xxxx(xxx-1,2-xxxxxxxxx), α-(xxxxxxxxxxxxx)-ω-xxxxxxx- |
37205-87-1 |
xxxxxxxxxx vyvolávající xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx prostředí) |
||
|
80. |
2-[2-(4-terc-nonylfenoxy)ethoxy]ethanol; ethanol, 2-[2-(4-xxxx-xxxxxxxxxxx)xxxxxx]- |
156609-10-8 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx REACH – xxxxxxx xxxxxxxxx) |
||
|
81. |
xxxx(xxx-1,2-xxxxxxxxx), α-(xxxxxxxxxx)-ω-xxxxxxx- xxxxxxxxxx, xxxxxxxxxxxx |
9016-45-9 |
xxxxxxxxxx vyvolávající xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
82. |
xxxxxxxxxxx: xxxxx x&xxxx;xxxxxxxxx x/xxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx s počtem 8 xxxxxx xxxxxxxxxx vázaných x&xxxx;xxxxxxx na xxxxxxxxx xxxxxx, zahrnující xxxxxx xxxxx, které obsahují xxxxxxxxx x&xxxx;xxxxxxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxxxx |
x-xxxxxxxxxx; 4-xxxxxxxxxx |
1806-26-4 |
217-302-5 |
xxxxxxxxxx xxxxxxxxxxxx narušení xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
83. |
4-(2,4,4-xxxxxxxxxxxxxxx-2-xx)xxxxx; 4-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxx; 4-(xxxx-xxxxx)xxxxx; xxxxx, 4-(1,1,3,3-xxxxxxxxxxxxxxxx)-; 4-xxxx-xxxxxxxxxx |
140-66-9 |
205-426-2 |
xxxxxxxxxx vyvolávající xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – životní xxxxxxxxx) |
|
|
84. |
xxxxxxxxxx; xxxxx, xxxxx- |
67554-50-1 |
266-717-8 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx činnosti (xx.&xxxx;57 xxxx. x) xxxxxxxx REACH – xxxxxxx xxxxxxxxx) |
|
|
85. |
xxxxx, 2-xxxxxxxx- |
86378-08-7 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx endokrinní xxxxxxxx (xx.&xxxx;57 písm. x) nařízení XXXXX – xxxxxxx xxxxxxxxx) |
||
|
86. |
xxxxx, xxxxxxxx-; xxxxxxxxxxxxx |
11081-15-5 |
234-304-1 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) nařízení XXXXX – xxxxxxx xxxxxxxxx) |
|
|
87. |
xxxxx, 2-xxxxx-; x-xxxxxxxxxx |
949-13-3 |
213-437-9 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. f) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
|
88. |
xxxxx, 2-sek-oktyl-; o-sek-oktylfenol |
26401-75-2 |
247-663-4 |
vlastnosti xxxxxxxxxxxx narušení xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx REACH – xxxxxxx xxxxxxxxx) |
|
|
89. |
xxxxx, 4-xxxxxxxx-; x-xxxxxxxxxxxxx |
27013-89-4 |
248-164-4 |
xxxxxxxxxx vyvolávající xxxxxxxx xxxxxxxxxx činnosti (xx.&xxxx;57 xxxx. x) nařízení XXXXX – xxxxxxx xxxxxxxxx) |
|
|
90. |
xxxxx, 4-sek-oktyl-; p-sek-oktylfenol |
27214-47-7 |
248-330-6 |
vlastnosti xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 písm. x) xxxxxxxx XXXXX – xxxxxxx prostředí) |
|
|
91. |
fenol, xxx-xxxxx-; xxx-xxxxxxxxxx |
93891-78-2 |
299-461-0 |
xxxxxxxxxx xxxxxxxxxxxx narušení xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 písm. x) xxxxxxxx REACH – xxxxxxx xxxxxxxxx) |
|
|
92. |
xxxxx, 4-(1-xxxxxxxxxx)-; x-(1-xxxxxxxxxx)xxxxx |
3307-00-4 |
221-989-7 |
xxxxxxxxxx xxxxxxxxxxxx narušení xxxxxxxxxx činnosti (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
|
93. |
xxxxx, 2-(1-dimethylheptyl)-; o-(1-methylheptyl)fenol |
18626-98-7 |
242-459-1 |
vlastnosti xxxxxxxxxxxx xxxxxxxx endokrinní činnosti (xx.&xxxx;57 písm. f) xxxxxxxx REACH – xxxxxxx xxxxxxxxx) |
|
|
94. |
xxxxx, 2-(1-xxxxxxxxxx)-; x-(1-xxxxxxxxxx)xxxxx |
17404-44-3 |
241-426-9 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx endokrinní xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – životní xxxxxxxxx) |
|
|
95. |
xxxxx, 2-(1-xxxxxxxxxxxx)-; x-(1-xxxxxxxxxxxx)xxxxx |
37631-10-0 |
253-574-1 |
xxxxxxxxxx vyvolávající xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. f) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
|
96. |
xxxxx, 4-(1-xxxxxxxxxxxx)-; x-(1-xxxxxxxxxxxx)xxxxx |
3307-01-5 |
221-990-2 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx činnosti (xx.&xxxx;57 xxxx. f) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
|
97. |
xxxxx, 2-(1-xxxxxxxxxxxx)-; x-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxx |
3884-95-5 |
223-420-8 |
xxxxxxxxxx xxxxxxxxxxxx narušení xxxxxxxxxx xxxxxxxx (čl. 57 xxxx. x) nařízení REACH – xxxxxxx xxxxxxxxx) |
|
|
98. |
xxxxx, (1,1,3,3-xxxxxxxxxxxxxxxx)-; (1,1,3,3-xxxxxxxxxxxxxxxx)xxxxx |
27193-28-8 |
248-310-7 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
|
99. |
xxxxx, (1-xxxxxxxxxxxx)-; (1-xxxxxxxxxxxx)xxxxx |
27985-70-2 |
248-759-9 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx činnosti (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
|
100. |
xxxxx, 4-(2-xxxxxxxxxxxx)- |
898546-19-5 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
101. |
xxxxx, 2-(2-xxxxxxxxxx)- |
28752-62-7 |
xxxxxxxxxx vyvolávající xxxxxxxx xxxxxxxxxx činnosti (xx.&xxxx;57 xxxx. x) nařízení XXXXX – xxxxxxx xxxxxxxxx) |
||
|
102. |
xxxxx, 4-(1-xxxxxxxxxxxx)-; x-(1-xxxxxxxxxxxx)xxxxx |
1818-08-2 |
217-332-9 |
xxxxxxxxxx vyvolávající xxxxxxxx endokrinní xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx prostředí) |
|
|
103. |
fenol, 4-(2-xxxxxxxxxx)- |
69468-20-8 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx REACH – xxxxxxx xxxxxxxxx) |
||
|
104. |
xxxxx, 4-(5-xxxxxxxxxxxx)- |
1824164-95-5 |
xxxxxxxxxx xxxxxxxxxxxx narušení xxxxxxxxxx činnosti (čl. 57 xxxx. f) nařízení XXXXX – xxxxxxx xxxxxxxxx) |
||
|
105. |
xxxxx, 2-(2-xxxxxxxxxxxx)- |
898546-20-8 |
xxxxxxxxxx vyvolávající xxxxxxxx xxxxxxxxxx činnosti (xx.&xxxx;57 písm. x) xxxxxxxx XXXXX – xxxxxxx prostředí) |
||
|
106. |
fenol, 4-(2-xxxxxxxxxxxx)- |
119747-99-8 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx endokrinní xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx REACH – xxxxxxx prostředí) |
||
|
107. |
fenol, 3-xxxxx- |
20056-69-3 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx činnosti (xx.&xxxx;57 xxxx. f) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
108. |
xxxxx, 2-(1,1-xxxxxxxxxxxxx)- |
1824575-79-2 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. f) xxxxxxxx XXXXX – xxxxxxx prostředí) |
||
|
109. |
fenol, 4-(1,1-xxxxxxxxxxxxx)- |
30784-29-3 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx endokrinní xxxxxxxx (xx.&xxxx;57 xxxx. x) nařízení REACH – xxxxxxx prostředí) |
||
|
110. |
fenol, 4-(5,5-xxxxxxxxxxxxx)- |
13330-52-4 |
xxxxxxxxxx xxxxxxxxxxxx narušení xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) nařízení XXXXX – xxxxxxx xxxxxxxxx) |
||
|
111. |
xxxxx, 2-(5,5-dimethylhexyl)- |
1822989-97-8 |
vlastnosti xxxxxxxxxxxx xxxxxxxx endokrinní xxxxxxxx (xx.&xxxx;57 písm. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
112. |
xxxxx, 3-(1,1-xxxxxxxxxxxxx)- |
70435-92-6 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (čl. 57 písm. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
113. |
xxxxx, 4-(1,4-xxxxxxxxxxxxx)- |
164219-26-5 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
114. |
xxxxxxxxxxx, xxxxxxxxxxxx: xxxxx s lineárním x/xxxx rozvětveným xxxxxxxxx xxxxxxxx x&xxxx;xxxxxx 8 xxxxxx xxxxxxxxxx xxxxxxxx x&xxxx;xxxxxxx xx xxxxxxxxx xxxxxx, xxxxxxxxxxxx, zahrnující xxxxxx látky, xxxxx xxxxxxxx jakýkoliv x&xxxx;xxxxxxxxxxxxxx xxxxxxx nebo xxxxxx xxxxxxxxx |
xxxx(xxx-1,2-xxxxxxxxx), α-[(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxx]-ω-xxxxxxx-; 2-(2-[4-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxxx]xxxxxx)xxxxxxx; xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx |
9036-19-5 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx endokrinní činnosti (xx.&xxxx;57 písm. x) xxxxxxxx XXXXX – xxxxxxx prostředí) |
|
|
115. |
2-[4-(2,4,4-trimethylpentan-2-yl)fenoxy]ethanol; poly(oxy-1,2-ethandiyl), α-[4-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxx]-ω-xxxxxxx-; xxxxxxxxxx, xxxxxxxxxxxx |
9002-93-1 |
xxxxxxxxxx xxxxxxxxxxxx narušení xxxxxxxxxx činnosti (xx.&xxxx;57 xxxx. f) xxxxxxxx XXXXX – životní xxxxxxxxx) |
||
|
116. |
20-[4-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxxx]-3,6,9,12,15,18-xxxxxxxxxxxxx-1-xx; 3,6,9,12,15,18-xxxxxxxxxxxxxx-1-xx, 20-[4-(1,1,3,3-tetramethylbutyl)fenoxy]- |
2497-59-8 |
219-682-8 |
vlastnosti xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx činnosti (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
|
|
117. |
xxxxxxx, 2-[4-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxxx]- |
2315-67-5 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (čl. 57 xxxx. x) xxxxxxxx XXXXX – životní xxxxxxxxx) |
||
|
118. |
xxxxxxx, 2-[2-[4-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxxx]xxxxxx]- |
2315-61-9 |
xxxxxxxxxx vyvolávající narušení xxxxxxxxxx xxxxxxxx (čl. 57 xxxx. f) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
119. |
3,6,9,12,15,18,21,24-xxxxxxxxxxxxxxxx-1-xx, 26-(4-xxxxxxxxxxx)- |
42173-90-0 |
255-695-5 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx činnosti (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx prostředí) |
|
|
120. |
poly(oxy-1,2-ethandiyl), α-(xxxxxxxxxx)-ω-xxxxxxx-, xxxxxxxxxx |
68987-90-6 |
xxxxxxxxxx vyvolávající xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – životní xxxxxxxxx) |
||
|
121. |
xxxx(xxx-1,2-xxxxxxxxx), α-[4-(6-xxxxxxxxxxxx)xxxxx]-ω-xxxxxxx- |
59379-12-3 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 písm. f) xxxxxxxx REACH – xxxxxxx prostředí) |
||
|
122. |
ethanol, 2-(4-xxxxxxxxxxx)-; 2-(x-xxxxxxxxxxx)xxxxxxx |
51437-89-9 |
257-203-4 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx REACH – životní prostředí) |
|
|
123. |
poly(oxy-1,2-ethandiyl), α-(4-xxxxxxxxxx)-ω-xxxxxxx- |
26636-32-8 |
xxxxxxxxxx xxxxxxxxxxxx narušení xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
124. |
xxxx(xxx-1,2-xxxxxxxxx), α-[4-(1-xxxxxxxxxxxx)xxxxx]-ω-xxxxxxx- |
73935-42-9 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
125. |
3,6,9,12,15,18-xxxxxxxxxxxxxx-1-xx, 20-(4-xxxxxxxxxxx)-; 20-(4-xxxxxxxxxxx)-3,6,9,12,15,18-xxxxxxxxxxxxx-1-xx |
32742-88-4 |
251-190-9 |
xxxxxxxxxx xxxxxxxxxxxx narušení endokrinní xxxxxxxx (xx.&xxxx;57 xxxx. x) nařízení XXXXX – xxxxxxx xxxxxxxxx) |
|
|
126. |
xxxxxxx, 2-[2-[2-[2-(4-xxxxxxxxxxx)xxxxxx]xxxxxx]xxxxxx]-; 2-(x-xxxxxxxxxxx)xxxxxxx |
51437-92-4 |
xxxxxxxxxx xxxxxxxxxxxx narušení xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. f) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
127. |
xxxxxxx, 2-[2-(4-oktylfenoxy)ethoxy]- |
51437-90-2 |
vlastnosti vyvolávající xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
128. |
3,6,9,12,15-xxxxxxxxxxxxxxxxxx-1-xx, 17-(4-xxxxxxxxxxx)- |
51437-94-6 |
xxxxxxxxxx xxxxxxxxxxxx narušení xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 písm. x) nařízení REACH – xxxxxxx prostředí) |
||
|
129. |
poly(oxy-1,2-ethandiyl), α-(xxxxxxxxxxxxx)-ω-xxxxxxx- |
9004-87-9 |
xxxxxxxxxx vyvolávající narušení xxxxxxxxxx činnosti (xx.&xxxx;57 xxxx. f) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
130. |
2-[2-[2-(4-xxxxxxxxxxx)xxxxxx]xxxxxx]xxxxxxx |
51437-91-3 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx činnosti (čl. 57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
131. |
3,6,9,12,15-xxxxxxxxxxxxxxxxxx-1-xx, 17-[4-(1,1,3,3-tetramethylbutyl)fenoxy]- |
2497-58-7 |
vlastnosti vyvolávající xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 písm. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
132. |
xxxxxxx, 2-[2-[2-[4-(1,1,3,3-tetramethylbutyl)fenoxy]ethoxy]ethoxy]- |
2315-62-0 |
vlastnosti xxxxxxxxxxxx narušení xxxxxxxxxx xxxxxxxx (čl. 57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
133. |
xxxxxxx, 2-[2-[2-[2-[4-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxxx]xxxxxx]xxxxxx]xxxxxx]- |
2315-63-1 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
134. |
3,6,9,12-xxxxxxxxxxxxxxxxxx-1-xx, 14-[4-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxxx]- |
2315-64-2 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx činnosti (xx.&xxxx;57 xxxx. f) xxxxxxxx REACH – xxxxxxx xxxxxxxxx) |
||
|
135. |
3,6,9,12,15,18,21,24-xxxxxxxxxxxxxxxx-1-xx, 26-[4-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxxx]- |
2315-65-3 |
xxxxxxxxxx xxxxxxxxxxxx narušení endokrinní xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
136. |
3,6,9,12,15,18,21,24,27-xxxxxxxxxxxxxxxx-1-xx, 29-[4-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxxx]- |
2315-66-4 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) nařízení XXXXX – xxxxxxx xxxxxxxxx) |
||
|
137. |
xxxxxxx, 2-[3-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxxx]- |
1026254-24-9 |
xxxxxxxxxx vyvolávající xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. f) xxxxxxxx REACH – xxxxxxx prostředí) |
||
|
138. |
ethanol, 2-[2-(1,1,3,3-xxxxxxxxxxxxxxxx)xxxxxx]- |
84658-53-7 |
xxxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. x) xxxxxxxx REACH – xxxxxxx xxxxxxxxx) |
||
|
139. |
xxxxxxx, 2-[2-(xxxxxxxxxxx)xxxxxx]- |
27176-92-7 |
xxxxxxxxxx xxxxxxxxxxxx narušení xxxxxxxxxx xxxxxxxx (xx.&xxxx;57 xxxx. f) xxxxxxxx XXXXX – xxxxxxx xxxxxxxxx) |
||
|
140. |
X,X-xxxxxxxxxxxxxxxx |
X,X-xxxxxxxxxxxxxxxx; xxxxxxxxxxxxxxxx; XXX |
68-12-2 |
200-679-5 |
xxxxxxx xxx xxxxxxxxxx xxx. 1X |
|
141. |
xxxx-2-xxxxxx |
xxxxxxxxx; 2-propenamid |
79-06-1 |
201-173-7 |
karcinogenní xxx. 1X/ xxxxxxxxx kat. 1B |
|
142. |
pyridin, xxxxxxxxxxxxx, x&xxxx;xxxxxxx ≥&xxxx;0,1&xxxx;% xxxxxxx (x.&xxxx;XX 200-753-7) |
68391-11-7 |
269-929-9 |
xxxxxxxxxxxx xxx. 1&xxxx;X/ xxxxxxxxx xxx. 1X |
|
|
143. |
xxxxxxxx |
xxxxxxxx |
91-22-5 |
202-051-6 |
xxxxxxxxxxxx xxx. 1X |
|
144. |
xxxxxxxxxxxxxxxxxxxxxxxxx |
xxxxxxxxxxxxxxxxxxxxxxxxx; 2-xxxxxxxxxxxxx, xxxxxxxxxx- |
97-99-4 |
202-625-6 |
xxxxxxx xxx xxxxxxxxxx xxx. 1X |
(1)&xxxx;&xxxx;Xxxxx pro xxxxxxxxxxx xxxxxxxxxx látek xxxxxxxxx x&xxxx;xxxxxxx xxxx xxxxxxxxx nečistota x&xxxx;xxxxxxxx xxxxxxxxx činí 0,1&xxxx;% (xxxxxxxxxxxx (xxxx.)), xxxx-xx x&xxxx;xxxx xxxxxxx uvedeno xxxxx.
(2)&xxxx;&xxxx;Xxxxx xxx přijatelnou xxxxxxxxxx této látky xxxx nezáměrné xxxxxxxxx x&xxxx;xxxxxxxx xxxxxxxxx xxxx 0,01&xxxx;% (xxxxxxxxxxxx (hmot.)), xxx xxxxxxxx specifickému xxxxxxxxxxxxxx xxxxxx stanovenému x&xxxx;xxxxxxx XX xxxxxxxx (XX) x.&xxxx;1272/2008.